Relapsed neuroblastomas show frequent RAS-MAPK pathway mutationsThomas F. Eleveld, John M. Maris, Derek A. Oldridge et al.|Nature Genetics|2015Cited by 563
Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent NeuroblastomaM. Emmy M. Dolman, Jan J. Molenaar, Evon Poon et al.|Clinical Cancer Research|2015Cited by 69
Supplementary Materials and Methods from Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent NeuroblastomaM. Emmy M. Dolman, Jan J. Molenaar, Evon Poon et al.|Unknown|2023Cited by 0
Supplementary Figure Legends from Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent NeuroblastomaM. Emmy M. Dolman, Jan J. Molenaar, Evon Poon et al.|Unknown|2023Cited by 0
Supplementary figures S1-8 from Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent NeuroblastomaM. Emmy M. Dolman, Jan J. Molenaar, Evon Poon et al.|Unknown|2023Cited by 0